Coelho Rogerio Vivaldi
CIK 1610381 · PRESIDENT AND CEO · last filed 2026-03-13
Coelho Rogerio Vivaldi is a PRESIDENT AND CEO who has filed 32 SEC Form 4 insider transactions across 6 companies since 2014. The most recent filing shows the insider sold $180.8K of CRNX on Mar 13, 2026. Across all open-market trades the lifetime net is −$3.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.52M
6
32
-$3.57M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRNX | Director | 16,823 | $34.47 | $579.9K | -$70.5K | 8 | 2026-03-13 |
| VTRS | Director | 45,351 | $16.48 | $747.4K | $0 | 4 | 2026-03-10 |
| Sigilon Therapeutics, Inc. (SGTX) Delisted | PRESIDENT AND CEO | 0 | $22.47 | $0 | $0 | 8 | 2023-08-11 |
| Bioverativ Inc. (BIVV) Delisted | EVP, Chief Global Therapeutics | 0 | — | — | $0 | 5 | 2018-03-08 |
| Spark Therapeutics, Inc. (ONCE) Delisted | Chief Commercial Officer | 20,116 | — | — | -$3.75M | 6 | 2016-07-19 |
| NERV | President and CEO | 41,667 | $4.51 | $187.9K | $250.0K | 1 | 2014-07-09 |
Recent Filings
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-13 | CRNX | Sell (S) | −5,000 | -$180.8K | EDGAR |
| 2026-03-10 | VTRS | Mixed | +24,835 | $0 | EDGAR |
| 2025-06-13 | CRNX | Grant (A) | +6,900 | $0 | EDGAR |
| 2025-03-10 | VTRS | Grant (A) | — | $0 | EDGAR |
| 2025-03-05 | VTRS | Exer (M) | +21,691 | $0 | EDGAR |
| 2024-06-11 | CRNX | Grant (A) | +3,400 | $0 | EDGAR |
| 2024-06-04 | VTRS | Grant (A) | — | $0 | EDGAR |
| 2023-08-11 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Disp (D) | −12,169 | $0 | EDGAR |
| 2023-07-24 | Sigilon Therapeutics, Inc. (SGTX) Delisted | Exer (M) | +5,528 | $106.4K | EDGAR |
| 2023-06-21 | CRNX | Grant (A) | +6,000 | $0 | EDGAR |